Soleil Boughton Sells 2,503 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the transaction, the insider now owns 164,363 shares of the company’s stock, valued at approximately $2,292,863.85. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $12.34 on Friday. The firm has a 50 day moving average price of $13.47 and a 200 day moving average price of $9.80. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. The business’s revenue was up 47.4% on a year-over-year basis. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HIMS. Citigroup increased their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. SVB Leerink initiated coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price for the company. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Wednesday, February 28th. Piper Sandler increased their price objective on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Finally, Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.85.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the business. Graham Capital Management L.P. lifted its position in shares of Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares in the last quarter. Swiss National Bank lifted its position in shares of Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after purchasing an additional 26,100 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after purchasing an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. bought a new stake in shares of Hims & Hers Health in the third quarter worth $1,596,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.